---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037559"
form_type: "8-K"
ticker: "MD"
cik: "0000893949"
company_name: "Pediatrix Medical Group, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T10:36:35.863316+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pediatrix Q2 net revenue $500.6M (+3% YoY); GAAP EPS $0.34, adjusted $0.39; EBITDA $59M

## Summary
- GAAP EPS from continuing ops $0.34 vs $0.36; adjusted EPS $0.39 vs $0.47 in prior year.
- Adjusted EBITDA $59.1M vs $65.6M YoY; 2023 EBITDA guidance reaffirmed at $235-245M.
- Same-unit revenue up 3.2% (reimbursement +2.6%, volume +0.6%); no CARES Act funds in Q2.
- Cash from ops $92.6M (+$11M YoY); capex $8.1M; total debt $675M.
- Weighted average shares fell to 82.7M from 85.6M due to share repurchases.

## SEC filing metadata
- accession: 0000950170-23-037559
- form_type: 8-K
- ticker: MD
- cik: 0000893949
- company_name: Pediatrix Medical Group, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/893949/000095017023037559/0000950170-23-037559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/893949/000095017023037559/md-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037559
- JSON: https://secwatch.observer/filing/0000950170-23-037559.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037559.txt

## Key facts
- Earnings Releases
  Pediatrix Medical Group, Inc. reported six months ended June 30, 2023 results: revenue $991.6 million, net income $42.5 million, EPS $0.52 per share.
  - Period: six months ended June 30, 2023
  - Revenue: $991.6 million
  - Net income: $42.5 million
  - EPS: $0.52 per share
  - Result: preliminary results
  source text: Operating Results from Continuing Operations – Six Months Ended June 30, 2023 For the six months ended June 30, 2023, Pediatrix generated revenue from continuing operations of $991.6 million, compared to $968.3 million for the prior-year period. Adjusted EBITDA from continuing operations for the six months ended June 30, 2023 was $99.2 million, compared to $116.2
  evidence_url: https://www.sec.gov/Archives/edgar/data/893949/000095017023037559/0000950170-23-037559-index.htm
- Earnings Releases
  Pediatrix Medical Group, Inc. reported three months ended June 30, 2023 results: revenue $500.6 million, net income $28.3 million, EPS $0.34 per diluted share.
  - Period: three months ended June 30, 2023
  - Revenue: $500.6 million
  - Net income: $28.3 million
  - EPS: $0.34 per diluted share
  - Result: preliminary results
  source text: reported Adjusted EPS from continuing operations of $0.39. For the 2023 second quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $501 million; • Income from continuing operations of $28 million; and • Adjusted EBITDA of $59 million. “Our second quarter operating results were in line with our expectations and reflect
  evidence_url: https://www.sec.gov/Archives/edgar/data/893949/000095017023037559/0000950170-23-037559-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.